Hjem › Ulcerøs kolitt › Utah
Kliniske studier for Ulcerøs kolitt i Utah
7 studier for Ulcerøs kolitt søker deltakere på steder i Utah.
Byer i Utah
Offisiell studietekst (engelsk)
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Care Access-Ogden, Ogden
- Advanced Research Institute - South Ogden, Ogden
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06598943A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- University of Utah Hospitals & Clinics, Salt Lake City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06979336A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- University of Utah, Salt Lake City
RekruttererFase 3
Alder 3 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06663332LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Care Access - Ogden, Ogden
RekruttererFase 2
Alder 18 til 80 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07186101A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- University of Utah Health, Salt Lake City
RekruttererFase 4
Alder 18 til 65 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06095128An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Velocity Clinical Research, Salt Lake City - Site Number: 8400147, West Jordan
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07184996Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- University of Utah Health, Salt Lake City
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 7. aug. 2026 · NCT05230173Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.